New Delhi: Drug firm Zydus Cadila Saturday said it has received the final nod from the US health regulator to market Clindamycin Phosphate and Benzoyl Peroxide gel, used in the treatment of acne. This combination medication is used to treat a certain type of acne (inflammatory acne vulgaris), the company said in a BSE filing. It also helps to decrease the number of acne pimples.
“Zydus Cadila has received the final approval from the USFDA to market Clindamycin Phosphate and Benzoyl Peroxide Gel, (US RLD -DUAC® Gel), 1.2 per cent/5 per cent.
“It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad,” it added.
Clindamycin is an antibiotic that stops the growth of acne-causing bacteria. Benzoyl peroxide can also stop the growth of bacteria as well as reduce oil production in the skin, it further said.
Latest posts by MD Team (see all)
- Recordati to seek Canadian approval for kidney disease drug Cystagon - April 17, 2019
- Wockhardt gets zero USFDA observations for Bioequivalence centre - April 16, 2019
- Amgen sets over Rs 15 lakh yearly price for new bone drug Evenity - April 16, 2019